Chemocentryx, Inc.

Jeff Jin

Yibin Zeng

Sreenivas Punna

Andrew M K Pennell

Solomon Ungashe

Trevor T Charvat

Wei Yu Chen

Daniel J Dairaghi

Zheng Wei

Jimmie L Moore

John Jessen Wright

Arindrajit Basak

Derek Hansen

Qiang Wang

Antoni Krasinski

Yandong Li

Cheng Hu

Anita Melikian

Andrew Mk Pennell

Jimmie Moore

Daniel Dairaghi

Andrew MK Pennell

Arindrajit Badak

Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

Heteroaryl sulfonamides and CCR2/CCR9

Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Triazolyl pyridyl benzenesulfonamides

Heteroaryl sulfonamides and CCR2

Growing community of inventors

Fremont, CA, United States of America

Jeff Jin